These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Yang Y; Blomme EA; Waring JF Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262 [TBL] [Abstract][Full Text] [Related]
5. Application of genomics in preclinical drug safety evaluation. Lord PG; Nie A; McMillian M Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814 [TBL] [Abstract][Full Text] [Related]
6. State-of-the-art genomics approaches in toxicology. Van Hummelen P; Sasaki J Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069 [TBL] [Abstract][Full Text] [Related]
7. Toxicogenomics concepts and applications to study hepatic effects of food additives and chemicals. Stierum R; Heijne W; Kienhuis A; van Ommen B; Groten J Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):179-88. PubMed ID: 16139318 [TBL] [Abstract][Full Text] [Related]
8. Toxicogenomics in predictive toxicology in drug development. Suter L; Babiss LE; Wheeldon EB Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278 [TBL] [Abstract][Full Text] [Related]
9. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. Ebbels TM; Keun HC; Beckonert OP; Bollard ME; Lindon JC; Holmes E; Nicholson JK J Proteome Res; 2007 Nov; 6(11):4407-22. PubMed ID: 17915905 [TBL] [Abstract][Full Text] [Related]
10. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886 [TBL] [Abstract][Full Text] [Related]
11. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Kramer JA; Sagartz JE; Morris DL Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090 [TBL] [Abstract][Full Text] [Related]
12. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Dambach DM; Andrews BA; Moulin F Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052 [TBL] [Abstract][Full Text] [Related]
13. The state-of-the-art in predictive toxicogenomics. Fielden MR; Kolaja KL Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120 [TBL] [Abstract][Full Text] [Related]
14. Applications of toxicogenomics to nonclinical drug development: regulatory science considerations. Sistare FD; Degeorge JJ Methods Mol Biol; 2008; 460():239-61. PubMed ID: 18449491 [TBL] [Abstract][Full Text] [Related]
15. Understanding mechanisms of toxicity: insights from drug discovery research. Houck KA; Kavlock RJ Toxicol Appl Pharmacol; 2008 Mar; 227(2):163-78. PubMed ID: 18063003 [TBL] [Abstract][Full Text] [Related]
16. Application of toxicogenomics to drug development. Lakkis MM; DeCristofaro MF; Ahr HJ; Mansfield TA Expert Rev Mol Diagn; 2002 Jul; 2(4):337-45. PubMed ID: 12138498 [TBL] [Abstract][Full Text] [Related]
17. Strategic applications of toxicogenomics in early drug discovery. Ryan TP; Stevens JL; Thomas CE Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379 [TBL] [Abstract][Full Text] [Related]
18. Modelling in vitro hepatotoxicity using molecular interaction fields and SIMCA. Clark RD; Wolohan PR; Hodgkin EE; Kelly JH; Sussman NL J Mol Graph Model; 2004 Jul; 22(6):487-97. PubMed ID: 15182808 [TBL] [Abstract][Full Text] [Related]
19. Predicting human liver microsomal stability with machine learning techniques. Sakiyama Y; Yuki H; Moriya T; Hattori K; Suzuki M; Shimada K; Honma T J Mol Graph Model; 2008 Feb; 26(6):907-15. PubMed ID: 17683964 [TBL] [Abstract][Full Text] [Related]